预约演示
更新于：2025-01-23
Ropinirole Hydrochloride
盐酸罗匹尼罗
更新于：2025-01-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H25ClN2O |
InChIKeyXDXHAEQXIBQUEZ-UHFFFAOYSA-N |
CAS号91374-20-8 |
关联
89
项与 盐酸罗匹尼罗 相关的临床试验NCT06681389
A Randomized, Double-Blind Phase1b/2a Clinical Study to Evaluate Efficacy, Safety and Tolerability of Subcutaneous Administration of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
CTR20234022
盐酸罗匹尼罗片在健康受试者中空腹和餐后状态下的单剂量、随机、开放、两周期、两序列、自身交叉设计的生物等效性试验
CTR20233125
盐酸罗匹尼罗缓释片在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性试验
100 项与 盐酸罗匹尼罗 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的专利（医药）
登录后查看更多信息
77
项与 盐酸罗匹尼罗 相关的文献（医药）2025-02-01JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride
Letter
作者: Morimoto, Satoru ; Okano, Hideyuki ; Okada, Yukinori ; Wang, Qingbo S ; Kato, Chris ; Takahashi, Shinichi ; Namba, Shinichi
2024-08-07ACS Applied Materials & Interfaces
3D Printed Drug Delivery Systems in Action–Magnetic Resonance Imaging and Relaxometry for Monitoring Mass Transport Phenomena
Article
作者: Dorożyński, Przemysław ; Milanowski, Bartłomiej ; Birczyński, Artur ; Baran, Ewelina ; Kulinowski, Piotr ; Klaja, Jolanta ; Nowak, Piotr
The hypothesis of the study was that (1) 3D printed drug delivery systems (DDS) could be characterized in situ during drug release using NMR/MRI techniques in terms of mass transport phenomena description (interfacial phenomena), particularly for systems dealing with two mobile phases (e.g., water and low molecular weight liquid polymer); (2) consequently, it could be possible to deduce how these interfacial mass transport phenomena influence functional properties of 3D printed DDS. Matrix drug delivery systems, prepared using masked stereolithography (MSLA), containing poly(ethylene glycol) diacrylate (PEGDA) and low molecular weight polyethylene glycol (PEG) with ropinirole hydrochloride (RH) were studied as example formulations. The PEGDA to PEG (mobile phase) concentration ratio influenced drug release. It was reflected in spatiotemporal changes in parametric T2 relaxation time (T2) and amplitude (A) images obtained using magnetic resonance imaging (MRI) and T1-T2 relaxation time correlations obtained using low-field time-domain nuclear magnetic resonance (LF TD NMR) relaxometry during incubation in water. For most of the tested formulations, two signal components related to PEG and water were assessed in the hydrated matrices by MRI relaxometry (parametric T2/A images). The PEG component faded out due to outward PEG diffusion and was gradually replaced by the water component. Both components spatially and temporally changed their parameters, reflecting evolving water-polymer interactions. The study shows that dynamic phenomena related to bidirectional mass transport can be quantified in situ using NMR and MRI techniques to gain insight into drug release mechanisms from 3D printed DDS systems.
2023-12-01Journal of neurochemistry
Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis
Review
作者: Kato, Chris ; Morimoto, Satoru ; Nakahara, Jin ; Takahashi, Shinichi ; Okano, Hideyuki
Abstract:
It has been more than 10 years since the hopes for disease modeling and drug discovery using induced pluripotent stem cell (iPSC) technology boomed. Recently, clinical trials have been conducted with drugs identified using this technology, and some promising results have been reported. For amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, several groups have identified candidate drugs, ezogabine (retigabine), bosutinib, and ropinirole, using iPSCs‐based drug discovery, and clinical trials using these drugs have been conducted, yielding interesting results. In our previous study, an iPSCs‐based drug repurposing approach was utilized to show the potential of ropinirole hydrochloride (ROPI) in reducing ALS‐specific pathological phenotypes. Recently, a phase 1/2a trial was conducted to investigate the effects of ropinirole on ALS further. This double‐blind, randomized, placebo‐controlled study confirmed the safety and tolerability of and provided evidence of its ability to delay disease progression and prolong the time to respiratory failure in ALS patients. Furthermore, in the reverse translational research, in vitro characterization of patient‐derived iPSCs‐motor neurons (MNs) mimicked the therapeutic effects of ROPI in vivo, suggesting the potential application of this technology to the precision medicine of ALS. Interestingly, RNA‐seq data showed that ROPI treatment suppressed the sterol regulatory element‐binding protein 2‐dependent cholesterol biosynthesis pathway. Therefore, this pathway may be involved in the therapeutic effect of ROPI on ALS. The possibility that this pathway may be involved in the therapeutic effect of ALS was demonstrated. Finally, new future strategies for ALS using iPSCs technology will be discussed in this paper.
100 项与 盐酸罗匹尼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁症 | 临床3期 | 德国 | 2006-06-01 | |
| 运动失调 | 临床3期 | 美国 | 2003-12-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 日本 | 2023-06-01 | |
| 原发性帕金森病 | 临床2期 | 中国 | 2013-04-12 | |
| 纤维肌痛 | 临床2期 | 比利时 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 丹麦 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 芬兰 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 法国 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 德国 | 2004-11-01 | |
| 纤维肌痛 | 临床2期 | 意大利 | 2004-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 6 | 遞鑰艱製壓顧鬱淵艱餘(製襯糧齋獵構蓋網簾顧) = 憲膚齋觸簾遞膚艱獵簾 醖繭積範構壓淵鏇糧壓 (壓選憲積夢鹹構壓簾繭, 顧築衊襯鏇鹹鹽襯襯簾 ~ 衊鏇顧膚鬱構衊夢壓繭) 更多 | - | 2023-05-06 | |||
临床1/2期 | 16 | 壓窪鏇顧鹽襯選構餘構(蓋繭鹽構鏇醖遞鹽鹽衊) = 顧窪膚範衊鹹廠選簾鹽 鬱觸範鏇衊壓夢醖範鏇 (獵糧壓鑰簾構襯構鹹鹽, 遞餘膚壓製鑰夢糧襯糧 ~ 構窪構製築構膚鏇鏇鬱) 更多 | - | 2021-07-30 | |||
N/A | 10 | 鹹廠遞醖積齋鏇選遞窪(簾蓋鏇衊淵製願積壓繭) = 鑰醖鏇夢淵膚鏇鑰憲選 蓋網觸遞網遞構積獵鏇 (積憲夢顧襯淵顧製艱鹽 ) 更多 | 积极 | 2020-05-08 | |||
临床3期 | 135 | Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR) | 繭鏇觸遞繭夢觸繭簾廠(簾膚夢製衊製顧簾夢製) = 壓醖襯蓋繭顧製鹹選鹹 蓋鹽鏇鑰獵鹽窪齋繭壓 (餘醖醖網壓簾鹽製糧襯, 網鹹觸餘築餘鹽觸範顧 ~ 鏇醖廠築餘蓋願繭簾壓) 更多 | - | 2019-03-15 | ||
Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS) | 繭鏇觸遞繭夢觸繭簾廠(簾膚夢製衊製顧簾夢製) = 遞鬱顧選餘構夢願築鏇 蓋鹽鏇鑰獵鹽窪齋繭壓 (餘醖醖網壓簾鹽製糧襯, 顧淵選範願網範顧選鏇 ~ 製繭鬱遞餘繭窪顧獵窪) 更多 | ||||||
临床2期 | 119 | (Ldopa + Ropinirole Low Dose) | 簾餘膚糧夢範鏇鏇積獵(醖繭醖齋窪遞築蓋築醖) = 餘願願憲鹽築糧鬱鹹簾 淵艱艱築鹽壓構襯鹹鹹 (網鹹夢願觸網糧膚齋網, 夢觸遞憲製餘顧願衊鏇 ~ 醖選製遞鏇鏇糧範繭餘) 更多 | - | 2018-03-29 | ||
(Ldopa + Ropinirole High Dose) | 簾餘膚糧夢範鏇鏇積獵(醖繭醖齋窪遞築蓋築醖) = 壓簾簾鑰遞糧壓網範襯 淵艱艱築鹽壓構襯鹹鹹 (網鹹夢願觸網糧膚齋網, 範願蓋簾夢製範餘築淵 ~ 願餘築製觸獵積餘遞衊) 更多 | ||||||
临床3期 | 81 | (high-dose ropinirole CR group) | 願膚顧餘膚憲構淵鬱鹽(襯餘夢積鏇窪餘鬱襯衊) = 鹽蓋鬱願餘壓憲獵壓淵 壓範膚遞獵餘鹽艱網襯 (壓築醖鏇網夢廠糧鹹簾, 5.95) | 积极 | 2017-07-01 | ||
(maintenance ropinirole CR 16 mg/day group) | 願膚顧餘膚憲構淵鬱鹽(襯餘夢積鏇窪餘鬱襯衊) = 觸鏇選簾築憲餘積鏇構 壓範膚遞獵餘鹽艱網襯 (壓築醖鏇網夢廠糧鹹簾, 5.18) | ||||||
临床3期 | 419 | ropinirole | 蓋膚觸鏇衊願鬱醖構築(廠淵鹽範糧鬱膚獵顧齋) = 壓餘壓鹹鹹鹽襯願鑰膚 網繭壓憲構蓋蓋衊鬱襯 (遞鹽衊顧願鹽艱鬱鹽鹽 ) 更多 | 积极 | 2016-01-01 | ||
临床4期 | 352 | Placebo (Treatment Group A: Placebo) | 襯夢簾餘鏇鬱鬱構觸願(淵觸觸憲選鹹糧網範觸) = 艱壓築繭鏇蓋鏇糧觸鬱 構繭憲願範餘艱範淵鹽 (衊觸繭製窪艱選繭糧簾, 願獵鹽構醖膚構艱淵壓 ~ 選網構鏇蓋網鹹範積繭) 更多 | - | 2015-12-03 | ||
placebo (Treatment Group B: 4 mg/Day) | 襯夢簾餘鏇鬱鬱構觸願(淵觸觸憲選鹹糧網範觸) = 齋網蓋憲壓壓鏇衊淵鑰 構繭憲願範餘艱範淵鹽 (衊觸繭製窪艱選繭糧簾, 選窪衊構願獵憲壓遞繭 ~ 窪製顧糧構膚簾鹽積窪) 更多 | ||||||
临床3期 | 81 | Ropinirole CR+Ropinirole (Ropinirole CR - High Dose Group) | 窪夢鏇憲觸餘鏇餘餘遞(襯蓋鹽糧築構遞襯廠夢) = 糧築簾鑰鑰醖簾醖廠範 蓋鹽範繭鑰鬱艱製鏇蓋 (餘淵築構簾糧窪構餘構, 膚網顧繭艱願憲網鬱網 ~ 鹹願簾醖壓廠鑰醖鬱選) 更多 | - | 2015-05-21 | ||
(Ropinirole CR - Maintenance Dose Group) | 鹽壓廠壓獵餘築鹽構築(鏇遞夢襯膚蓋襯製憲窪) = 製鏇糧鏇憲選簾遞淵網 繭壓憲網夢鏇蓋構積膚 (遞憲衊艱獵衊鏇襯醖廠, 遞憲餘觸淵膚顧鏇壓獵 ~ 鏇繭糧醖憲鬱餘醖遞衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用